ARDELYX, INC. Restricted Cash and Cash Equivalents, Noncurrent
ARDELYX, INC. (ARDX) had Restricted Cash and Cash Equivalents, Noncurrent of $100.00 thousand as of 2016-03-31, per its 10-Q filed 2016-05-09.
Discontinued › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:RestrictedCashAndCashEquivalentsNoncurrent · last filed 2017-02-17
- 2016-03-31: Restricted Cash and Cash Equivalents, Noncurrent $100.00K.
- 2015-12-31: Restricted Cash and Cash Equivalents, Noncurrent $100.00K.
- 2015-09-30: Restricted Cash and Cash Equivalents, Noncurrent $100.00K.
- 2015-06-30: Restricted Cash and Cash Equivalents, Noncurrent $100.00K.
| Period end | Restricted Cash and Cash Equivalents, Noncurrent |
|---|---|
| 2016-03-31 | $100.00K 10-Q · filed 2016-05-09 |
| 2015-12-31 | $100.00K 10-K · filed 2017-02-17 |
| 2015-09-30 | $100.00K 10-Q · filed 2015-11-12 |
| 2015-06-30 | $100.00K 10-Q · filed 2015-08-12 |
| 2015-03-31 | $100.00K 10-Q · filed 2015-05-12 |
| 2014-12-31 | $100.00K 10-K · filed 2016-03-04 |
| 2014-09-30 | $204.00K 10-Q · filed 2014-11-07 |
| 2014-06-30 | $180.00K 10-Q · filed 2014-08-08 |
| 2013-12-31 | $180.00K 10-K · filed 2015-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |